Botanix Pharmaceuticals

26/08/2026

Botanix Releases Annual Report

The FY2026 Annual Report has been released, reflecting the first full year of Sofdra’s launch. Total prescriptions shipped for Sofdra (sofpironium) grew to 105,794 in FY2026.

View Report - https://app.sharelinktechnologies.com/announcement-preview/asx/95c7be6c2321999847be438dd0daf673

$BOT

29/07/2026

Commercial dermatology company, Botanix Pharmaceuticals (ASX:BOT) is pleased to provide a recording from the recent investor webinar presented by Executive Chairman Vince Ippolito, Chief Executive Officer Dr Howie McKibbon, PharmD/MBA and US Chief Financial Officer Chris Lesovitz, CPA.

The webinar shared comprehensive insights into the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report and provide an update for Sofdra® (sofpironium).

📺 Watch video - https://youtu.be/9o67NKD8S80

Download quarterly report - https://app.sharelinktechnologies.com/announcement-preview/asx/3f98e890ea37a8303c186d65d2d99600

27/07/2026

$BOT released Q4 Quarterly Reports. Sofdra quarterly shipments grew 25% to 33,358 and hit a record 12,895 shipments in June.

View Reports - https://buff.ly/xpu5rJ9

20/07/2026

Quarterly Update Webinar | Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on 27 July at 11:00 am AEST / 9:00 am AWST for an important update.

Register via - https://janemorganmanagement-au.zoom.us/webinar/register/1917842508839/WN_DDbb-6p2TJuMhsbIGeil5w #/registration

$BOT

13/07/2026

Notice of Allowance for US patent on Sofdra® drug substance

A Notice of Allowance received for a US patent application covering the ‘crystalline form of sofpironium bromide and preparation method thereof’ aims to protect Sofdra’s drug substance from unauthorised commercial manufacturing into May 2040.

View Release - https://app.sharelinktechnologies.com/announcement-preview/asx/13406ff89030e0465d06717c351971e3

$BOT

08/07/2026

Botanix (ASX:BOT) received an Intention to Grant from the European Patent Office for its sofpironium topical gel applicator. Once validated, this IP protection runs until May 2039—giving ~13 more years of runway!

Read more: https://stocksdownunder.com/botanix-pharmaceuticals-asxbot-european-applicator-patent/

$BOT.ax

Botanix Pharmaceuticals (ASX:BOT) has secured a European patent Intention to Grant on the Sofdra applicator, running to May 2039 and reshaping its ex-US

07/07/2026

Botanix Pharmaceuticals Limited (ASX:BOT) announces that the European Patent Office has issued an Intention to Grant, for European patent application, EP 19799730.7, ‘Applicator and System for Pharmaceutical Preparation and Method of Use’, which covers proprietary applicator technology used with sofpironium topical gel, 12.45%, the drug product branded as Sofdra® in the US.

Read full announcement: https://buff.ly/bYu5vvz

$BOT

21/04/2026

📆 Quarterly Update Webinar | Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on 29 April at 10.30 am AEST / 8.30 am AWST for an important update.

Pre-register: https://botanixpharma.zoom.us/webinar/register/WN_6xiTQOIzTuyb6726lE5yQQ #/registration

$BOT

26/02/2026

Half Year Webinar 3 March | Registration Open

Join our executive team for the Company’s Half Year Financial Report Webinar on 3 March at 11 am AEDT (Sydney/Melbourne)/8 am AWST (Perth) for an important update.

Pre-register here: https://us06web.zoom.us/webinar/register/WN_8BQalV5cRuaR5_c-S5Dh_g

$BOT

26/01/2026

Quarterly Activity and 4C Quarterly Cash Flow Reports for Q2 FY26 have been released. Quarter over quarter, total prescriptions shipped for Sofdra® (sofpironium) grew 24% to 25,351, and net revenue increased 28% to $9.1 million.

Read the reports here: https://bit.ly/3Zwa1cn

$BOT